{
    "paper_id": "PMC7140250",
    "metadata": {
        "title": "ICER's timelines for assessments extended due to COVID-19",
        "authors": []
    },
    "body_text": [
        {
            "text": "In response to the COVID-19 pandemic, the Institute for Clinical and Economic Review (ICER) has announced extended timelines for pending assessments.1 The healthcare providers and insurers, life sciences companies and patient advocates who make significant contributions to the review process are currently otherwise engaged with the health crisis.",
            "cite_spans": [
                {
                    "start": 149,
                    "end": 150,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "Changes of note include the indefinite postponement of the public meetings for sickle cell disease and cystic fibrosis (CF). The public comment period will remain open until 25 March for the CF Draft Evidence Report, pushing the publication of the revised report out to around 23 April. After publication of the ulcerative colitis Draft Evidence Report on 15 April all deadlines and input opportunities will be delayed by 2\u22123 months. Similarly, reviews of hemophilia A, bladder cancer and digital apps for opioid use disorder have been put on hold for 2\u22123 months, however the supervised injection facilities timelines are unchanged, as an extra two months had already been allocated.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "\nDraft Evidence Report released on obeticholic acid\n",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "ICER has now released its Draft Evidence Report, incorporating initial input from patients, clinicians and stakeholders, appraising the comparative value and effectiveness of obeticholic acid, from Intercept Pharmaceuticals Inc., in nonalcoholic steatohepatitis (NASH).2 In line with the other extensions, allowing clinicians to respond to the COVID-19 pandemic, public comment will now be accepted on this draft until 24 June, then the revised Evidence Report will be discussed at a public meeting of one of ICER's independent evidence appraisal committees, provisionally scheduled for August 2020. The draft is interim only, pending further input and should not be taken as final. Stakeholders can now register for the meeting and should submit formal comments, or requests to make oral comment, by email.",
            "cite_spans": [
                {
                    "start": 269,
                    "end": 270,
                    "mention": "2",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "\"We are hopeful these expanded timeframes will enable all stakeholders to instead focus on meeting the needs of their patient communities during this national emergency,\" said the statement. Timeline updates will be posted on the ICER website.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}